Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
This is a phase II, randomized, double-blinded, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs.
- Trial name
- NCT06917313
- Testing
- Fezolinetant
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yale University
Lymphedema, Fibrosis
Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost
The purpose of the study is to investigate the difference in late radiation morbidity between hypofractionated and normofractionated loco-regional breast irradiation irrespective of mastectomy or lumpectomy.
- Trial name
- NCT02384733
- Testing
- Loco-regional RT
- Where
- Denmark
- Volunteers
- 2,963 people
- Sponsor
- Danish Breast Cancer Cooperative Group
Breast Cancer
Hypofractionated Whole-breast Irradiation With Simultaneously Integrated Boost For Early-Stage Breast Cancer After Breast-conserving Surgery
The study was designed to evaluate the feasibility and safety of hypofractionated whole-breast irradiation with simultaneously integrated boost for early-stage breast cancer after breast conserving surgery in Chinese population.
- Trial name
- HF-WBI-SIB (NCT02617043)
- Testing
- hypofractionated whole breast irradiation with simultaneously integrated boost
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Breast Cancer, Early-stage Breast Cancer
Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
This is a prospective, single-center, randomize-controlled study. The purpose of this study is to evaluate the efficacy of neoadjuvant CDK4/6 inhibitors in patients with high-risk EPclin multigene risk analysis and non-response…
- Trial name
- NeoMARS (NCT06650748)
- Testing
- Dalpiciclib, Letrozole
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University
Breast Cancer
Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial
The purpose of this study is to determine the cost-effectiveness of biennial screening with mammography and MRI compared to mammography alone in women aged 50-75 years and who show > 75% mammographic density.
- Trial name
- NCT01315015
- Testing
- Contrast enhanced breast MRI
- Where
- 9 sites in Netherlands
- Volunteers
- 40,373 people
- Sponsor
- UMC Utrecht
Early Breast Cancer, Locally Advanced Breast Cancer
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home…
- Conditions
- Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
- Trial name
- ProHer (NCT05415215)
- Testing
- Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Where
- 45 sites in Argentina, Bosnia and Herzegovina and 15 more
- Volunteers
- 346 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod
Stereotactic radiation has been implemented more than 3 decades ago, initially to radiate benign and later malignant tumors within the brain. Doses up to 24 Gy in one session have been used.
- Trial name
- NCT03581136
- Testing
- Dose Fractionation
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
This proposal is for a Window of Opportunity (WOO) clinical trial using a novel combination of two Health Canada approved agents, cemiplimab (Libtayo) and dupilumab (Dupixent), for off label use in early-stage estrogen receptor…
- Trial name
- NCT05967884
- Testing
- Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Operable Breast Neoplasms
Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer
The hypothesis to be addressed in this randomized phase III trial is that 4 months of letrozole may be superior to surgery as primary therapy for early stage hormone receptor positive breast cancer in postmenopausal women…
- Trial name
- REAL (NCT00908531)
- Testing
- letrozole (Femara)
- Where
- 9 sites in Denmark
- Volunteers
- 123 people
- Sponsor
- Danish Breast Cancer Cooperative Group
Breast Cancer
Effect of Metformin on Breast Cancer Metabolism
Metformin, a drug that has been used since the 1950's in the treatment of diabetes, has recently generated great interest in its anticancer effects based on in vitro, in vivo and clinical studies.
- Trial name
- NCT01266486
- Testing
- Metformin
- Where
- 3 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- Oxford University Hospitals NHS Trust
TNBC, TNBC - Triple-Negative Breast Cancer
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
This is a single arm phase II trial combination of ivonescimab and carbo-docetaxel every 3 weeks for 6 cycles in patients with early-stage triple negative breast cancer.
- Conditions
- TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
- Trial name
- NCT07017673
- Testing
- Ivonescimab, Carboplatin, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Cedars-Sinai Medical Center
Breast Cancer
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with trastuzumab + QL1209 + docetaxel compared with trastuzumab + pertuzumab + docetaxel in the participants with early-stage…
- Trial name
- NCT04629846
- Testing
- Trastuzumab, QL1209, Pertuzumab
- Where
- 2 sites in China
- Volunteers
- 517 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Early Stage Breast Cancer
A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients
Single arm, prospective, multi-center, non-randomized study of subjects treated with single fraction, intra-operative radiation therapy at the time of lumpectomy for early stage breast cancer.To assess the rate of ipsilateral…
- Trial name
- NCT03561454
- Testing
- IORT
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MedStar Franklin Square Medical Center
Metastatic Breast Cancer
Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy
EILEEN was a non-interventional/observational, retrospective, multi-center, real life cohort study conducted in 14 private and academic oncology clinics in Turkey.
- Trial name
- NCT06619704
- Where
- United States
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer Female, Locally Advanced Breast Cancer
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
The purpose of this study is to test the efficacy, safety and tolerability of a combination of immunotherapy and anticancer drugs presurgery in patients with hormone-receptor positive breast cancer.
- Conditions
- Breast Cancer Female, Locally Advanced Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast
- Trial name
- NCT04088032
- Testing
- Abemaciclib, durvalumab and aromatase inhibitor
- Where
- United States
- Sponsor
- Alison Stopeck
Breast Diseases, Breast Neoplasms
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
This study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2…
- Conditions
- Breast Diseases, Breast Neoplasms, Dalpiciclib, Endocrine Breast Diseases
- Trial name
- NCT07581834
- Testing
- Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- Where
- 2 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Fujian Cancer Hospital
Cancer, Leukemia
Early Ageing During Therapy in AYA Cancer Patients
Longitudinal cohort study; measurements before start of systemic therapy and one year later.
- Conditions
- Cancer, Leukemia, Hodgkin Lymphoma, Testicular Cancer
- Trial name
- NCT05062707
- Testing
- Blood sampling
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- University Medical Center Groningen
This Study Evaluates Interventions to Increase Surveillance Mammography Uptake for Early Breast Cancer Detection Among Singaporean Women
Trial to Evaluate the Impact of Various Behavioural Interventions to Increase Mammography Uptake Among Singaporean Women
Breast cancer is the leading cancer among women in Singapore, yet mammography screening rates remain critically low at 34.7%, despite the availability of a national program since 2002.
- Trial name
- PROMPT (NCT07283107)
- Testing
- Arm 2: One mailed reminder, Arm 3: Two mailed reminders, Arm 4: Mailed reminder with prescheduled appointment
- Where
- Singapore
- Volunteers
- 8,910 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Breast Cancer
CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study
To determine the impact on Interpreting Physician performance in detecting breast cancer, as defined by the area under the Receiver Operating Characteristic Curve (ROC), when Automated Breast Ultrasound (ABUS) and screening…
- Trial name
- NCT01424956
- Testing
- Automated Breast Ultrasound (ABUS)
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- U-Systems, Inc.
Early-stage Breast Cancer, Pain Syndrome
Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients
The REaCT TAPS clinical trial will compare a tapering dose of dexamethasone to other standards of care on the presence of taxane-associated pain syndrome (TAPS) in early stage breast cancer.
- Trial name
- REaCT-TAPS (NCT03348696)
- Testing
- Dexamethasone tapering dose, Dexamethasone physician choice
- Where
- 2 sites in Canada
- Volunteers
- 124 people
- Sponsor
- Ottawa Hospital Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.